Precipio, Inc. (PRPO:NASDAQ) closed at $19.57 on November 4, 2026, up 5.10% on the day. The stock trades 41.8% below its 52-week high of $33.63 and 10.0% above its 52-week low of $17.79. Over the past year, it lost 5.2%. Precipio, Inc. is part of the Capital Goods sector (Biotechnology: Laboratory Analytical Instruments).
In 252 trading sessions since November 4, 2025, PRPO closed higher on 117 days (46%). Its best day was August 19, 2026 (+12.80%) and its worst was February 5, 2026 (-10.34%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 1 time.
Transgenomic, Inc., a biotechnology company, engages in advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies, and clinical and research services primarily in the United States. The company provides genetic analytical laboratory services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical and biotechnology companies. It employs various genomic testing service technologies, including ICE COLD-PCR, a proprietary platform technology that enables detection of multiple known and unknown mutations from virtually any sample type, including tissue biopsies, blood, urine, saliva, cell-free DNA, and circulating tumor cells. The company was founded in 1997 and is headquartered in Omaha, Nebraska.
Find more stocks like PRPO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.